Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolys BioPharmaTSE:4588 -2.06%40 Quick Ratio is 9.54 as of Dec. 2025, which is 1% below its 10-year median of 9.64. GuruFocus rates TSE:4588 with a GF Score™ of 40/100 and a GF Value™ of 円363.33 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Oncolys BioPharma ranks better than 60.88% on this metric.
Oncolys BioPharma has a quick ratio of 9.54. It generally indicates good short-term financial strength.
The historical rank and industry rank for Oncolys BioPharma's Quick Ratio or its related term are showing as below:
TSE:4588'
s Quick Ratio Range Over the Past 10 Years
Min: 5.11 Med: 9.64 Max: 13.33
Current: 5.11
During the past 13 years, Oncolys BioPharma's highest Quick Ratio was 13.33. The lowest was 5.11. And the median was 9.64.
TSE:4588's Quick Ratio is ranked better than 60.88% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs TSE:4588: 5.11
Oncolys BioPharma (TSE:4588) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Oncolys BioPharma Quick Ratio Related Terms
Oncolys BioPharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4588 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Oncolys BioPharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolys BioPharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Oncolys BioPharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Oncolys BioPharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolys BioPharma (TSE:4588) has a Quick Ratio of 9.54 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Oncolys BioPharma and its competitors. This is near median its historical median of 9.64. Over the past decade, Oncolys BioPharma's Quick Ratio has ranged from 5.11 to 13.33. According to the industry distribution chart, Oncolys BioPharma ranks #552 out of 1411 companies in the Biotechnology industry, placing it in the top 39.1%.
Is Oncolys BioPharma's Quick Ratio too high?
Oncolys BioPharma's current Quick Ratio of 9.54 is near median its 10-year median of 9.64. Over the past 10 years, this metric has ranged from a low of 5.11 to a high of 13.33. The Biotechnology industry median Quick Ratio is 3.59. Oncolys BioPharma's value of 9.54 is 165.7% above this industry median. Based on the distribution chart, Oncolys BioPharma ranks #552 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncolys BioPharma ranks #552 out of 1411 companies for Quick Ratio. This puts Oncolys BioPharma in the upper half of its industry. The industry median Quick Ratio is 3.59. Oncolys BioPharma's value of 9.54 is 165.7% above this benchmark. Historically, Oncolys BioPharma's own Quick Ratio has ranged from 5.11 to 13.33 over the past decade. While the company's 10-year median is 9.64 vs. the industry median of 3.59, Oncolys BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncolys BioPharma's current Quick Ratio of 9.54 is 165.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Oncolys BioPharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncolys BioPharma's current Quick Ratio is 9.54, which is near median its own 10-year median of 9.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円363.33, compared to a current price of 円2,522.00 — trading 594.1% above its estimated fair value. The current Quick Ratio is 9.54, which is near median its 10-year median of 9.64 and 165.7% above the Biotechnology industry median of 3.59. Oncolys BioPharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Quick Ratio is 9.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円2,522.00 is trading 594.1% above its estimated GF Value™ of 円363.33.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
Quick Ratio: 9.54 (near median its 10-year median of 9.64)
GF Value™: 円363.33 vs. price of 円2,522.00 (594.1% above fair value)
Industry Position: 165.7% above the Biotechnology median (#552 of 1411)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
